The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”.
The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms.
” This patent was granted in Europe last year and it is pleasing that we are now expanding the patent protection geographically to include Australia. The development work of the inhalation platform continues internally as well as in collaboration with external partners and we are currently conducting a toxicological study program for the platform”, says Adam Feiler, CTO Nanologica.
NLAB Spiro® is a scalable drug delivery platform consisting of micrometre sized spherical porous silica particles, fully soluble in simulated lung fluid, where APIs are encapsulated inside the pores of the silica particles. Formulation of drugs through NLAB Spiro® can improve solubility and/or the bioavailability of an API. NLAB Spiro® protects an API from degradation, provides a controlled release profile, and enables local treatment with lowered systemic effects, which creates new treatment options for lung diseases.
The platform is currently undergoing a toxicological study program for NLAB Spiro®, with the first results expected during the summer.
For further information, please contact:
Johanna Johansson, IR Manager Nanologica
Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface characteristics of silica particles. Through the two business areas, Drug Development and Chromatography, we strive towards reducing healthcare disparities throughout the world for the betterment of mankind. In Drug Development, we are committed to leverage our technology platform to solve medical problems in order to provide new treatments for patients with severe lung diseases. In Chromatography, we aim to make insulin available to more patients in need by reducing the production cost for manufacturers. Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
About NLAB Spiro®
NLAB Spiro® is Nanologica’s technology platform for inhalation. The platform is constituted of biologically degradable nanoporous silica particles that can be loaded with APIs inside the pores of the particles. The particles are spherical, non-aggregating and appears as a free-flowing powder. The aerodynamical properties are tailored for inhalation and the particle size ranges between 2 µm and 5 µm, which means they can reach a desired part of the lung – the smaller the particle, the deeper into the lung it can reach. Once reaching the lung, the API is released giving a treatment effect locally. NLAB Spiro™ can improve solubility and/or the bioavailability of an API, protect an API from degradation, provide a controlled release profile, and enable local treatment with lowered systemic effects, which creates new treatment options for lung diseases.